MILESTONE SCIENTIFIC INC.
Business
Milestone Scientific Inc. develops and commercializes proprietary computer-controlled drug delivery systems featuring Dynamic Pressure Sensing® Technology that controls flow rate and measures pressure at the needle tip in real time. The company offers dental products marketed as CompuDent® and STA Single Tooth Anesthesia System® utilizing The Wand® handpiece, and medical products including the CompuFlo® Epidural Computer Controlled Anesthesia System for epidural procedures. Products are distributed in the United States, Canada, and more than 40 other countries through direct sales, e-commerce platforms, and third-party distributor relationships in dental and medical markets.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Product sales, net | 9 | 9 | 10 | 9 | 10 | |
| Cost of products sold | 3 | 2 | 3 | 4 | 4 | |
| Gross profit | 6 | 6 | 7 | 5 | 6 | |
| Selling, general and administrative expenses | 12 | 12 | 13 | 13 | 13 | |
| Research and development expenses | 449,469 | 858,767 | 701,378 | 1 | 878,210 | |
| Depreciation and amortization expense | 78,195 | 37,448 | 61,912 | 63,755 | 73,836 | |
| Total operating expenses | 12 | 13 | 14 | 14 | 14 | |
| Loss from operations | −6 | −7 | −7 | −9 | −7 | |
| Interest (expense) income, net | −25,599 | 60,265 | — | — | — | |
| Gain on sale of net operating losses | — | 2 | — | — | — | |
| Loss before provision for income taxes | −6 | −5 | −7 | −9 | — | |
| Provision for income taxes | — | — | 0 | 0 | −333 | |
| Net loss | −6 | −5 | −7 | −9 | −7 | |
| Net loss per share applicable to common stockholders - basic | −0.07 | −0.06 | −0.1 | −0.12 | −0.1 | |
| Net loss per share applicable to common stockholders - diluted | −0.07 | −0.06 | — | — | −0.1 | |
| Weighted average shares outstanding and to be issued - basic | 82 | 80 | 73 | 71 | 69 | |
| Weighted average shares outstanding and to be issued - diluted | 82 | 80 | — | — | 69 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 1 | 3 | 3 | 9 | 15 | |
| Prepaid expenses and other current assets | 468,792 | 564,645 | 517,785 | 443,872 | 375,360 | |
| Inventories | 4 | 4 | 3 | 2 | 2 | |
| Advances on contracts | 1 | 1 | 1 | 1 | 1 | |
| Total current assets | 7 | 9 | 11 | 13 | 19 | |
| Furniture, fixtures and equipment, net | 19,193 | 12,921 | 10,024 | 18,146 | 23,713 | |
| Intangibles, net | 79,063 | 148,404 | — | — | — | |
| Right of use assets finance lease | 55,811 | 67,201 | 8,998 | 17,645 | 26,294 | |
| Right of use assets operating lease | 150,378 | 257,842 | 355,235 | 443,685 | 524,217 | |
| Other assets | 24,150 | 24,150 | 24,150 | 24,150 | 24,150 | |
| Total assets | 8 | 10 | 11 | 14 | 20 | |
| Current portion of finance lease liabilities | 27,347 | 12,530 | 10,264 | 9,365 | 8,545 | |
| Current portion of operating lease liabilities | 130,355 | 116,279 | 103,427 | 91,701 | 81,001 | |
| Total current liabilities | 4 | 4 | 3 | 3 | 3 | |
| Non-current portion of finance lease liabilities | 27,336 | 54,672 | 434 | 10,698 | 20,062 | |
| Non-current portion of operating lease liabilities | 35,208 | 165,573 | 281,853 | 385,279 | 476,980 | |
| Convertible notes payable, related parties | 800,000 | — | — | — | — | |
| Total liabilities | 5 | 4 | 3 | 4 | 4 | |
| Commitments and contingencies | — | — | — | — | — | |
| Common stock, par value $0.001; authorized 125,000,000 shares; 80,486,449 shares issued and 80,453,116 shares outstanding as of December 31, 2025; 78,047,798 shares issued and 78,014,465 shares outstanding as of December 31, 2024; | 80,487 | 78,048 | 75,881 | 69,306 | 68,153 | |
| Additional paid in capital | 137 | 135 | 132 | 127 | 125 | |
| Accumulated deficit | −134 | −128 | −123 | −116 | −108 | |
| Treasury stock, at cost, 33,333 shares | −911,516 | −911,516 | −911,516 | −911,516 | −911,516 | |
| Total Milestone Scientific, Inc. stockholders equity | 3 | 6 | 8 | 10 | 16 | |
| Total liabilities and stockholders equity | 8 | 10 | 11 | 14 | 20 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 8,853 | 7,218 | 12,999 | 14,180 | 22,205 | |
| Amortization of intangibles | 69,341 | 30,232 | 49,320 | 49,663 | 51,630 | |
| Stock based compensation | 952,716 | 1 | 1 | 1 | 790,915 | |
| Bad debt expense | 11,639 | — | 24,865 | — | — | |
| Employees paid in stock | 728,750 | 364,953 | 417,500 | 317,265 | 793,110 | |
| Expense paid in stock | 1 | 579,801 | 745,999 | 747,351 | 707,861 | |
| Amortization of right-of-use asset | 107,463 | 97,393 | 88,450 | 80,533 | 73,552 | |
| (Increase) in accounts receivable | −216,883 | −162,712 | 356,188 | 0 | 137,384 | |
| Increase in accounts receivable, related parties | −25,548 | — | 356,188 | 249,555 | — | |
| Increase in inventories | −68,622 | −1 | −1 | −833,121 | 878,666 | |
| (Increase ) decrease in advances on contracts | −133,134 | 96,288 | — | — | — | |
| Decrease (increase) in prepaid expenses and other current assets | 95,853 | −46,860 | −73,912 | −68,512 | 40,555 | |
| Increase in accounts payable | 408,856 | 331,789 | −413,125 | 322,300 | 297,456 | |
| Increase in accounts payable, related party | 866,386 | 82,801 | −392,981 | 407,636 | 10,719 | |
| (Decrease) increase in accrued expenses | −801,116 | 70,610 | 386,882 | −292,495 | 562,824 | |
| (Decrease) increase in accrued expenses, related party | −115,887 | 167,104 | −30,361 | −246,692 | −47,493 | |
| Decrease operating right of use lease asset | −103,751 | −94,991 | −83,054 | −72,353 | 81,942 | |
| Net cash used in operating activities | −3 | −3 | −5 | −6 | −4 | |
| Purchase of furniture, fixtures, and equipment | −15,124 | −10,124 | — | −8,527 | −15,189 | |
| Sale of marketable securities | — | 3 | 5 | 0 | — | |
| Net cash (used in) provided by investing activities | −15,124 | 3 | −3 | −8,527 | −15,189 | |
| Net proceeds from public placement offering | — | 192,156 | — | — | — | |
| Proceeds from issuance of convertible notes, related parties | 800,000 | — | — | — | — | |
| Net Proceeds exercise of warrants | — | 51,751 | 0 | 0 | 3 | |
| Payments finance lease obligations | −13,665 | −10,136 | −9,366 | −8,544 | −8,648 | |
| Net cash provided by financing activities | 786,335 | 233,771 | 3 | −8,544 | 5 | |
| Net increase (decrease) in cash and cash equivalents | −2 | 280,345 | −6 | −6 | 540,429 | |
| Initial recognition of finance lease-right of use asset | — | −68,340 | — | — | — | |
| Initial recognition of finance lease-right of use liabilities | — | 68,340 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is MILESTONE SCIENTIFIC INC.'s CIK number?
MILESTONE SCIENTIFIC INC.'s SEC CIK number is 0000855683 (855683). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find MILESTONE SCIENTIFIC INC.'s SEC filings?
All of MILESTONE SCIENTIFIC INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.